CO-DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | +1.38% |
|
-8.18% | +9.77% |
| 06-14 | Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform | CI |
| 05-13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15.52 | 262.9 | 260.4 | 77.91 | 40.67 | 45.35 | - |
| Enterprise Value (EV) 1 | 15.52 | 262.9 | 260.4 | 77.91 | 40.67 | 45.35 | 45.35 |
| P/E ratio | -2.49 x | 6.12 x | 7.26 x | -5.6 x | -1.11 x | -1.09 x | -1.26 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 72.2 x | 3.53 x | 2.66 x | 2.28 x | 5.97 x | 28.5 x | 30.2 x |
| EV / Revenue | 72.2 x | 3.53 x | 2.66 x | 2.28 x | 5.97 x | 28.5 x | 30.2 x |
| EV / EBITDA | - | 6,284,706 x | 4,998,919 x | -25,156,840 x | - | - | - |
| EV / FCF | - | - | 6,443,620 x | - | - | - | - |
| FCF Yield | - | - | 0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,340 | 28,269 | 29,160 | 30,918 | 30,581 | 31,278 | - |
| Reference price 2 | 0.8952 | 9.300 | 8.930 | 2.520 | 1.330 | 1.450 | 1.450 |
| Announcement Date | 30/03/20 | 25/03/21 | 24/03/22 | 16/03/23 | 14/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.215 | 74.55 | 97.89 | 34.22 | 6.812 | 1.593 | 1.5 |
| EBITDA | - | 41.83 | 52.09 | -3.097 | - | - | - |
| EBIT 1 | -5.894 | 41.69 | 46.06 | -26.98 | -42.71 | -42.28 | -42.7 |
| Operating Margin | -2,741.66% | 55.93% | 47.06% | -78.85% | -626.92% | -2,654.36% | -2,846.67% |
| Earnings before Tax (EBT) 1 | -6.196 | 42.57 | 45.64 | -18.85 | -38.11 | -41.01 | -42.58 |
| Net income 1 | -6.196 | 42.48 | 36.66 | -14.24 | -35.33 | -41.04 | -42.58 |
| Net margin | -2,882.06% | 56.98% | 37.45% | -41.61% | -518.68% | -2,576.08% | -2,838.33% |
| EPS 2 | -0.3600 | 1.520 | 1.230 | -0.4500 | -1.200 | -1.330 | -1.150 |
| Free Cash Flow | - | - | 40.41 | - | - | - | - |
| FCF margin | - | - | 41.28% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | 77.58% | - | - | - | - |
| FCF Conversion (Net income) | - | - | 110.24% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 30/03/20 | 25/03/21 | 24/03/22 | 16/03/23 | 14/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.4 | 22.7 | 5.023 | 5.094 | 1.401 | 0.602 | 0.1978 | 2.457 | 3.555 | 0.4678 | 0.375 | 0.375 | 0.375 | 0.4 | 0.4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 10.31 | 9.824 | -4.147 | -6.536 | -26.12 | -9.951 | -11.99 | -8.936 | -11.83 | -10.26 | -10.68 | -10.68 | -10.68 | - | - |
| Operating Margin | 50.53% | 43.28% | -82.56% | -128.29% | -1,863.84% | -1,653.04% | -6,063.62% | -363.68% | -332.62% | -2,192.88% | -2,846.67% | -2,846.67% | -2,846.67% | - | - |
| Earnings before Tax (EBT) 1 | 10.24 | 13.1 | -3.428 | -3.476 | -25.04 | -8.015 | -11.16 | -8.096 | -10.84 | -9.289 | -10.56 | -10.58 | -10.6 | - | - |
| Net income 1 | 7.498 | 11.71 | -2.686 | -1.361 | -21.91 | -5.755 | -8.919 | -5.982 | -14.68 | -9.312 | -10.56 | -10.58 | -10.6 | - | - |
| Net margin | 36.75% | 51.61% | -53.48% | -26.72% | -1,563.02% | -956.11% | -4,508.79% | -243.47% | -412.82% | -1,990.39% | -2,814.67% | -2,820% | -2,825.33% | - | - |
| EPS 2 | 0.2500 | 0.3400 | -0.0800 | -0.0400 | -0.6800 | -0.2000 | -0.3100 | -0.2000 | -0.5000 | -0.3100 | -0.3400 | -0.3400 | -0.3400 | -0.3400 | -0.3400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 16/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 14/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | 40.4 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 27.3% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | 22.9% | - | - | - | - |
| Assets 1 | - | - | 160 | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 0.11 | 0.77 | 0.67 | 1.43 | - | - | - |
| Capex / Sales | 52.68% | 1.04% | 0.68% | 4.17% | - | - | - |
| Announcement Date | 30/03/20 | 25/03/21 | 24/03/22 | 16/03/23 | 14/03/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.45
USD
Average target price
2
USD
Spread / Average Target
+37.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.77% | 45.35M | |
| -34.21% | 14.7B | |
| -52.23% | 2.33B | |
| +23.01% | 1.96B | |
| -10.06% | 1.52B | |
| +21.24% | 1.24B | |
| -23.46% | 904M | |
| +1.33% | 784M | |
| -34.13% | 750M | |
| +23.58% | 597M |
- Stock Market
- Equities
- CODX Stock
- Financials Co-Diagnostics, Inc.
